Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1172/jci.insight.145785 http://scihub22266oqcxt.onion/10.1172/jci.insight.145785 33529170!8021111!33529170     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       JCI+Insight 2021 ; 6 (5): ä Nephropedia Template TP {{tp|p=33529170|t=2021. Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2 |pdf=|usr=}}{{33529170}} gab.com Text Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2 JO: JCI Insight http://www.kidney.de/pget.php?&tw=1&pmid=33529170 #FOAvip The development of prophylactic and therapeutic agents for coronavirus disease 2019 (COVID-19) is a current global health priority. Here, we investigated the presence of cross-neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in dromedary camels that were Middle East respiratory syndrome coronavirus (MERS-CoV) seropositive but MERS-CoV free. The tested 229 dromedaries had anti-MERS-CoV camel antibodies with variable cross-reactivity patterns against SARS-CoV-2 proteins, including the S trimer and M, N, and E proteins. Using SARS-CoV-2 competitive immunofluorescence immunoassays and pseudovirus neutralization assays, we found medium-to-high titers of cross-neutralizing antibodies against SARS-CoV-2 in these animals. Through linear B cell epitope mapping using phage immunoprecipitation sequencing and a SARS-CoV-2 peptide/proteome microarray, we identified a large repertoire of Betacoronavirus cross-reactive antibody specificities in these dromedaries and demonstrated that the SARS-CoV-2-specific VHH antibody repertoire is qualitatively diverse. This analysis revealed not only several SARS-CoV-2 epitopes that are highly immunogenic in humans, including a neutralizing epitope, but also epitopes exclusively targeted by camel antibodies. The identified SARS-CoV-2 cross-neutralizing camel antibodies are not proposed as a potential treatment for COVID-19. Rather, their presence in nonimmunized camels supports the development of SARS-CoV-2 hyperimmune camels, which could be a prominent source of therapeutic agents for the prevention and treatment of COVID-19. Twit Text FOAVip Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2 ????JCI Insight http://www.kidney.de/pget.php?&tw=1&pmid=33529170 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33529170 #FOAvip English Wikipedia <ref>{{Cite pmid|33529170}}</ref> Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2 #MMPMID33529170 Chouchane L; Grivel JC; Farag EABA; Pavlovski I; Maacha S; Sathappan A; Al-Romaihi HE; Abuaqel SW; Ata MMA; Chouchane AI; Remadi S; Halabi N; Rafii A; Al-Thani MH; Marr N; Subramanian M; Shan J JCI Insight 2021[Mar]; 6 (5): ä PMID33529170show ga The development of prophylactic and therapeutic agents for coronavirus disease 2019 (COVID-19) is a current global health priority. Here, we investigated the presence of cross-neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in dromedary camels that were Middle East respiratory syndrome coronavirus (MERS-CoV) seropositive but MERS-CoV free. The tested 229 dromedaries had anti-MERS-CoV camel antibodies with variable cross-reactivity patterns against SARS-CoV-2 proteins, including the S trimer and M, N, and E proteins. Using SARS-CoV-2 competitive immunofluorescence immunoassays and pseudovirus neutralization assays, we found medium-to-high titers of cross-neutralizing antibodies against SARS-CoV-2 in these animals. Through linear B cell epitope mapping using phage immunoprecipitation sequencing and a SARS-CoV-2 peptide/proteome microarray, we identified a large repertoire of Betacoronavirus cross-reactive antibody specificities in these dromedaries and demonstrated that the SARS-CoV-2-specific VHH antibody repertoire is qualitatively diverse. This analysis revealed not only several SARS-CoV-2 epitopes that are highly immunogenic in humans, including a neutralizing epitope, but also epitopes exclusively targeted by camel antibodies. The identified SARS-CoV-2 cross-neutralizing camel antibodies are not proposed as a potential treatment for COVID-19. Rather, their presence in nonimmunized camels supports the development of SARS-CoV-2 hyperimmune camels, which could be a prominent source of therapeutic agents for the prevention and treatment of COVID-19. |Animals[MESH] |Antibodies, Neutralizing/*immunology/pharmacology[MESH] |Antibodies, Viral/immunology[MESH] |Betacoronavirus/immunology[MESH] |COVID-19/immunology[MESH] |Camelus/*immunology/virology[MESH] |Cross Reactions[MESH] |Epitopes[MESH] |Female[MESH] |Humans[MESH] |Middle East Respiratory Syndrome Coronavirus/immunology[MESH] |SARS-CoV-2/*drug effects/*immunology[MESH] |Severe acute respiratory syndrome-related coronavirus/immunology[MESH]Dromedary camels as a natural source of neutralizing nanobodies agains(epmc).pdf DeepDyve Pubget Overpricing